ArticleBlood neoplasia2026

Favezelimab plus pembrolizumab for anti-PD-1-refractory classic Hodgkin lymphoma: an open-label phase 1/2 study.

John Timmerman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.